Viking Therapeutics, Inc.
Viking Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $3.76B market cap.
Most recent reported earnings: Q2 FY2026 (Jul 28, 2026).
19 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 |
Spoken Alpha tracks VKTX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 4/10 quarters with 30% positive reaction rate
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for VKTX.
$ curl https://api.spokenalpha.com/v1/companies/VKTXFAQ
Spoken Alpha indexes VKTX's earnings call transcripts at https://spokenalpha.com/companies/VKTX. Each call links to attributed speakers and parsed analyst Q&A. Viking Therapeutics, Inc.'s own investor relations page is at https://ir.vikingtherapeutics.com/.
Viking Therapeutics, Inc. (VKTX) held its most recent earnings call on 2026-02-11, covering fiscal Q4 2025.
Viking Therapeutics, Inc. (VKTX) operates in the Healthcare sector (Biotechnology industry).
| 2026-07-28 |
| — |
| $-1.23 |
| — |
| — |
| — |
| — |
EODHD |
Source: EODHD. VKTX reported actuals as published; sparse fields render as —.
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 2 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $2.34 | $2.53 | -7.4% | +5.9% | +6.5% |
| Q4 FY2025 | $2.34 | $2.29 | +2.3% | +6.4% | +9.2% |
| Q3 FY2025 | $2.43 | $2.51 | -3.0% | -1.9% | -4.6% |
| Q2 FY2025 | $2.57 | $2.54 | +1.1% | -4.4% | -3.2% |
| Q1 FY2024 | $2.71 | $2.58 | +4.9% | +0.9% | +3.2% |
CFO since 2024 • 2/4 beats (50%) • guidance suspended Q1 FY2025
| Q4 FY2024 |
| $2.47 |
| $2.55 |
| -3.0% |
| -4.5% |
| -2.2% |
| Q3 FY2024 | $2.24 | $2.41 | -7.0% | -1.6% | -3.3% |
| Q2 FY2024 | $2.27 | $2.43 | -6.6% | -2.1% | -0.8% |
| Q1 FY2023 | $2.76 | $2.57 | +7.2% | -1.6% | -2.6% |
| Q4 FY2023 | $2.45 | $2.62 | -6.6% | -0.1% | -1.0% |